文献速递浆细胞疾病

复发/难治性多发性骨髓瘤患者接受泊马度胺联合地塞米松±皮下注射达雷妥尤单抗治疗的健康相关生活质量:APOLLO试验的患者报告结局

Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial.
PubMed 文献 · Am J Hematol · 2022-02-06

APOLLO III期试验中,达雷妥尤单抗联合泊马度胺和地塞米松(D-Pd)较Pd使复发/难治性多发性骨髓瘤患者疾病进展或死亡风险降低37%。本文报告患者报告结局:D-Pd组中位治疗11.5个月,Pd组6.6个月,两组PRO依从性高且相似;D-Pd组生理和情绪功能、疾病症状及治疗不良反应维持基线水平,Pd组则恶化;D-Pd组在多个时间点疼痛和疲乏较Pd组减轻(p<0.05)。

要点

  • D-Pd组中位治疗11.5个月,Pd组6.6个月,两组PRO依从性高且相似。
  • D-Pd组生理和情绪功能、疾病症状及治疗不良反应维持基线水平,Pd组恶化。
  • D-Pd组在多个时间点疼痛和疲乏较Pd组减轻(p<0.05)。

核心结论

  • 在Pd基础上加用达雷妥尤单抗后患者健康相关生活质量保持稳定,多项结果支持D-Pd优于Pd。
  • 这些发现补充了D-Pd的显著临床改善,并支持其在复发/难治性多发性骨髓瘤患者中的使用。

研究设计与样本

  • III期APOLLO试验的患者报告结局分析,纳入既往接受≥1线治疗(包括来那度胺和蛋白酶体抑制剂)的复发/难治性多发性骨髓瘤患者。
  • 比较达雷妥尤单抗联合泊马度胺和地塞米松(D-Pd)与泊马度胺和地塞米松(Pd)的患者报告结局。

主要发现

  • D-Pd组中位治疗持续时间11.5个月,Pd组6.6个月。
  • 两组PRO依从率均高且相似。
  • 两组EORTC QLQ-C30总体健康状况评分均未观察到较基线的变化。
  • D-Pd组生理和情绪功能、疾病症状及治疗不良反应维持基线水平,Pd组则恶化。
  • D-Pd组在多个时间点疼痛和疲乏较Pd组减轻(p<0.05)。

关键数值与推荐

  • D-Pd较Pd使疾病进展或死亡风险降低37%。
  • D-Pd组中位治疗持续时间11.5个月,Pd组6.6个月。
  • D-Pd组在多个时间点疼痛和疲乏较Pd组减轻(p<0.05)。

临床怎么用

  • 原文结论支持D-Pd在复发/难治性多发性骨髓瘤患者中的使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the phase 3 APOLLO trial, daratumumab in combination with pomalidomide and dexamethasone (D-Pd) significantly reduced the rate of disease progression or death by 37% relative to Pd alone in patients with relapsed/refractory multiple myeloma (RRMM) who had received ≥1 prior line of therapy including lenalidomide and a proteasome inhibitor. Here, we present patient-reported outcomes (PROs) from APOLLO. Median treatment duration was 11.5 months with D-Pd and 6.6 months with Pd. PRO compliance rates were high and similar in both groups. No changes from baseline were observed for EORTC QLQ-C30 global health status scores in either group, while physical and emotional functioning, disease symptoms, and adverse effects of treatment remained at baseline levels with D-Pd but worsened with Pd. Reductions (p < 0.05) in pain and fatigue were seen at several time points with D-Pd versus Pd. Overall, these results suggest patients' health-related quality of life remained stable when daratumumab was added to Pd, with several results favoring D-Pd versus Pd. These findings complement the significant clinical improvements observed with D-Pd and support its use in patients with RRMM.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Terpos E, Dimopoulos MA, Boccadoro M, et al. Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial. Am J Hematol. 2022. PMID: 35089607. doi:10.1002/ajh.26480

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。